Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine HIPEC and Dacarbazine for Locally Recurrent Uterine Leiomyosarcoma
NCT04727242Phase 2Completed
- Sponsor
- Stanford University
- Start
- Jan 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, dacarbazine in uterine leiomyosarcoma (uLMS), sponsored by Stanford University. Started Jan 2021; status: completed.
02
Drugs
gemcitabinedacarbazine
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT04727242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727242.